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Although graft survival following renal transplantation (RTx) has improved,  outcomes following high-
risk RTx are variable.  Preexisting antibodies,  including donor-speciﬁc antibodies (DSA),  play an 
important role in graft dysfunction and survival.  We have designed a study to investigate the safety 
and eﬃcacy of anti-CD20 monoclonal antibodies (rituximab) in high-risk RTx recipients.  Major eligi-
bility criteria include: 1) major and minor ABO blood group mismatch,  2) positive DSA.  Thirty-ﬁve 
patients will receive 200mg/body of rituximab.  The primary endpoint is the incidence of B cell deple-
tion.  This study will clarify whether rituximab is eﬃcacious in improving graft survival in high-risk 
RTx recipients.
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T he incidence of end-stage renal disease has been increasing throughout the world.  Renal trans-
plantation (RTx) is the most eﬀective and economical 
method of renal replacement therapy.  RTx results in 
better quality of life and patient survival compared 
with hemodialysis or continuous ambulatory peritoneal 
dialysis [1].  Although graft survival following RTx 
has improved,  graft survival following high-risk RTx 
remains poor.  Preexisting and de novo antibodies,  
including donor-speciﬁc antibodies (DSA),  play an 
important role in graft dysfunction,  longevity,  and 
loss [2].  Hence,  treatment must focus on B cell sup-
pression,  as B cells are the source of donor-speciﬁc 
antibody production.  Rituximab is an anti-CD20 
monoclonal antibody that depletes circulating CD20＋ 
B cells and plasma cells.  Rituximab is used to treat 
non-Hodgkinʼs lymphoma and the lymphocyte predomi-
nant subtype of Hodgkinʼs lymphoma [3].  Recently,  it 
has been used to prevent or treat antibody-mediated 
RTx rejection (AMR) [4-6] and antibody-mediated 
glomerulonephritis,  including focal glomerular sclero-
sis (FGS) [7].  However,  with the exception of ABO 
blood group major mismatch,  rituximab has not been 
approved by the Japanese health care system for use 
in RTx.  We postulate that rituximab may reduce the 
incidence of AMR and antibody-mediated glomerulone-
phritis in Japanese RTx recipients.
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Endpoints
　 The aim of this study is to evaluate the eﬃcacy and 
safety of rituximab in Japanese RTx recipients.  The 
primary outcome is the incidence of B cell depletion,  
AMR and recurrent glomerulonephritis.  Secondary 
outcome measures include medication-related toxicity.
Study Design
　 The study is a single-arm,  prospective,  non-ran-
domized,  open label,  single center investigation to 
evaluate the safety and eﬃcacy of rituximab in high-
risk RTx recipients.  Fig.  1 shows an overview of the 
study design.  The study periods are from Sep/17th/ 
2014 to Mar/31st/2018.
Eligibility Criteria
　 All patients who meet the main inclusion and exclu-
sion criteria will be invited for screening.  The main 
inclusion and exclusion criteria are listed in Table 1.  
Of note,  rituximab was approved by the Japanese 
national health care system for ABO blood group 
major mismatch RTx in February,  2016.  However,  
the inclusion criteria remained unchanged because 
very little eﬀectiveness data have been made available.  
Written informed consent will be obtained before any 
screening or inclusion procedure.  The study was 
designed in compliance with the principles of the 
Declaration of Helsinki,  and the protocol was 
approved by the institutional review boards of our 
hospital (approval no. m14013).  The study was regis-
tered with the UMIN Clinical Trials Registry (UMIN-
CTR),  Japan (UMIN 000018769).  The participants 
reviewed the informed consent document and received 
individual counseling with a thorough discussion of 
alternative treatment,  including nonparticipation.
Treatment Methods
　 Treatment will be composed of 2 sequential 
phases: the induction phase and the renal transplanta-
tion phase.  In the induction phase,  200mg/body of 
rituximab will be administered over 5h,  1 to 2 weeks 
prior to RTx.  We chose a dose of 200mg/body 
despite the fact that 375mg/m2 has been approved,  
due to a recent study that demonstrated moderate 
toxicity with the 375mg/m2 dose [3].  The prior study 
indicated that lower doses of rituximab are eﬀective 
at depleting B cells in the spleen and in the peripheral 
blood [8].  As the evaluation of the primary endpoint,  
The B cells in the peripheral blood will be counted 3 
days prior to RTx using ﬂow cytometry.  If we ﬁnd 
that the B cell count is not 0 at this time point,  an 
additional dose of 200mg/body of rituximab will be 
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Eligibility criteria
1. Major and minor ABO blood group mismatch
2. Positive donor-speciﬁc antibodies
3. Focal glomerular sclerosis
4. Antibody-mediated rejection
5. Recurrent glomerulonephritis
Rituximab 200mg/body
Renal transplantation
Primary endpoint:
the incidence of
• B cell depletion
• Antibody mediated rejection
• Recurrent glomerulonephritis
Design:　　　　　　　　  a single-arm, prospective, non-randomized, open label,
　　　　　　　　　　　　single center study
Enrollment　　　　　　　35
Location:　　　　　　　  Okayama University Hospital
UMIN registration No.　　000018769
Fig. 1　 Study des ign .  
Rituximab will be administered 
1 to 2 weeks prior to RTx.  The 
absence of B cells in the 
peripheral blood will be con-
ﬁrmed 1 week after the admin-
istration.  If the B cell count is 
not 0,  an additional dose of 
200mg/body of rituximab will 
be administered.
administered.  In the renal transplantation phase,  RTx 
will be performed within 2 weeks following the ﬁrst 
dose of induction rituximab therapy.  In case of post 
transplantation setting,  the B cells in the peripheral 
blood will be counted one week following the adminis-
tration.  Vital signs,  laboratory tests including com-
plete blood count,  the comprehensive metabolic panel,  
and urine analysis will be checked by 1 day after the 
administration.  The incidence of any infection will be 
documented within one year of the administration.
Statistical Consideration
　 The primary end points are deﬁned as:
1. the absence of B cells after the initial administra-
tion
2. the presence of antibody- mediated rejection
3. the presence of recurrent glomerulonephritis includ-
ing focal segmental glomerulosclerosis
4. nadir serum creatinine levels after the administra-
tion
　 Antibody-mediated rejection and/or recurrent focal 
segmental glomerulosclerosis were diagnosed by ele-
vated serum creatinine and clinical course.  Biopsy is 
performed whenever possible.  Those are followed for 
1 year.
　 The secondary end point is deﬁned as safety,  
including any possible adverse events.  On average,  12 
patients undergo RTx at our institution each year.  We 
anticipate that 10 patients will require rituximab each 
year.  A total of 35 patients will be included in the 
trial.  All statistical analyses will be conducted using 
JMP software (ver. 11; SAS,  Cary,  NC,  USA).
Discussion
　 We have designed a clinical study to determine the 
eﬀects of rituximab in the pre- and/or post- transplan-
tation setting.  The study will clarify whether ritux-
imab is safe and eﬃcacious in high-risk Japanese RTx 
recipients.  It will provide new and important data on 
the eﬀectiveness of rituximab,  speciﬁcally in Japanese 
RTx recipients.
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Table 1　 Patient eligibility
Inclusion criteria
　 All ages
　 Patients with any of the following high-risk factors:
　　1. ABO incompatible (major mismatch)
　　2. ABO minor mismatch
　　3. donor speciﬁc antibody positive
　　4. original disease of focal glomerular sclerosis
　　5. original disease of recurrent glomerulonephritis
　　6. antibody-mediated rejection
　 Written informed consent
Exclusion criteria
　 A patient who does not meet inclusion criteria
　 A patient who meets inclusion criteria,  but whom the authors 
judge to be inappropriate for the study
